Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency
H.C. Wainwright Global Investment Conference
Stay informed and receive company updates straight to your inbox.